Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00026624 · ClinicalTrials.gov registry record · Phase 1
Safety/Immunogenicity of Immunizations of ALVAC-DC-SC vs ALVAC-SC
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
NCT00026624: Completed Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00026624 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00026624, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
The purpose of this study is to determine how safe it is to give patients a shot that has a mixture of a vaccine and dendritic cells (DCs), a special kind of immune cell, and how safe it is to give a shot of the vaccine alone. Current HIV vaccines have not been strong enough to give good immune responses. Research has shown that the immune response to a vaccine delivered by DCs is greater than the response without DC delivery. A5130 is a study that seeks to give good delivery of the vaccine to important immune cells of the body.
Interventions
- BIOLOGICAL ALVAC(2)120(B,MN)GNP (vCP1452)
- DRUG Keyhole-Limpet Hemocyanin
Trial Details
| Field | Value |
|---|---|
| Est. Completion | 2006-10 |
| Phase | Phase 1 |
What the finished NCT00026624 record still lists
NCT00026624 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which ALVAC(2)120(B,MN)GNP (vCP1452) is the first listed.
NCT00026624 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00026624 about?
NCT00026624 is a clinical study titled "Safety/Immunogenicity of Immunizations of ALVAC-DC-SC vs ALVAC-SC". The purpose of this study is to determine how safe it is to give patients a shot that has a mixture of a vaccine and dendritic cells (DCs), a special kind of immune cell, and how safe it is to give a shot of the vaccine alone. Current HIV vaccines have not been strong enough to give good immune res...
What is the current status of trial NCT00026624?
This trial is currently completed. It is a Phase 1 study. Estimated completion is 2006-10.
What interventions are being tested in trial NCT00026624?
The interventions under investigation include: ALVAC(2)120(B,MN)GNP (vCP1452) (BIOLOGICAL), Keyhole-Limpet Hemocyanin (DRUG).
Who is sponsoring clinical trial NCT00026624?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.